Janvier Serumondo
23 Papers
17 Citations
Janvier Serumondo is an academic researcher. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 6, co-authored 14 publications.
Chat about Author
Papers
Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda.
Jean Damascene Makuza,Jean Olivier Twahirwa Rwema,Corneille Killy Ntihabose,Donatha Dushimiyimana,Justine Umutesi,Marie Paul Nisingizwe,Janvier Serumondo,Muhamed Semakula,David J. Riedel,Sabin Nsanzimana +9 more
TL;DR: The first national estimate of the prevalence of HBsAg seropositivity and its associated factors in Rwanda is provided and people with the highest risk of HBV infection should be the priority of future prevention efforts in Rwanda and in similar settings.
Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa
Grace Umutesi,Fabienne Shumbusho,Fredrick Kateera,Janvier Serumondo,Jules Kabahizi,Emmanuel Musabeyezu,Alida Ngwije,Neil Gupta,Neil Gupta,Sabin Nsanzimana +9 more
TL;DR: In low-middle income countries, several programmes have developed national strategies or plans for viral hepatitis control, but many do not specifically target elimination, and most lack high-level endorsement or successful steps towards implementation.
42
Innovative strategies for a successful SLMTA country programme: The Rwanda story
Innocent Nzabahimana,Sabin Sebasirimu,John B. Gatabazi,Emmanuel Ruzindana,Claver Kayobotsi,Mary K. Linde,Jean Baptiste Mazarati,Edouard Ntagwabira,Janvier Serumondo,Georges Dahourou,Wangeci Gatei,Claude Mambo Muvunyi +11 more
TL;DR: This study describes the achievements of Rwandan laboratories four years after the introduction of SLMTA, using the SLIPTA scoring system to measure laboratory progress and shows improvement in quality management systems.
Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population.
Justine Umutesi,Carol Y. Liu,Michael J Penkunas,Jean Damascene Makuza,Corneille Killy Ntihabose,Sabine Umuraza,julienne niyikora,Janvier Serumondo,Neil Gupta,Neil Gupta,Sabin Nsanzimana +10 more
TL;DR: Results suggest that over 55% of individuals who screened positive for HCV-antibodies were chronically infected, and targeted screening for older individuals is recommended, given the association between age and infection.
16
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Neil Gupta,Linda Manirambona,Fabienne Shumbusho,Jules Kabihizi,Anthere Murangwa,Janvier Serumondo,Jean Damascene Makuza,Sabin Nsanzimana,Claude Mambo Muvunyi,Constance Mukabatsinda,Emmanuel Musabeyezu,Gregory Camus,Philip M. Grant,Fredrick Kateera +13 more
TL;DR: This single-arm prospective trial aimed to evaluate the safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for the treatment of adults in Rwanda with chronic HCV infection, predominantly of genotype 4, and a history of direct-acting antiviral treatment failure.
11